Allogene Therapeutics Inc
ALLO1.100USD
+0.020+1.85%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
240.46MCap. mercado
PérdidaP/E TTM
Más Datos de Allogene Therapeutics Inc Compañía
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.
Información de la empresa
Símbolo de cotizaciónALLO
Nombre de la empresaAllogene Therapeutics Inc
Fecha de salida a bolsaOct 11, 2018
Director ejecutivoDr. David D Chang, M.D., Ph.D.
Número de empleados226
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 11
Dirección210 East Grand Avenue
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Teléfono16504572700
Sitio Webhttps://allogene.com/
Símbolo de cotizaciónALLO
Fecha de salida a bolsaOct 11, 2018
Director ejecutivoDr. David D Chang, M.D., Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
7.56M
-3.60%
Dr. David D Chang, M.D., Ph.D.
Dr. David D Chang, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
5.72M
-7.46%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
478.17K
-0.90%
Mr. Joshua A. Kazam
Mr. Joshua A. Kazam
Director
Director
303.06K
--
Mr. Owen N. Witte, M.D.
Mr. Owen N. Witte, M.D.
Independent Director
Independent Director
292.83K
+14.59%
Mr. Benjamin Machinas (Ben) Beneski
Mr. Benjamin Machinas (Ben) Beneski
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
218.51K
--
Mr. Earl Martin Douglas, Esq.
Mr. Earl Martin Douglas, Esq.
Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary
Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary
110.21K
-5.49%
Dr. Zachary Roberts, M.D., Ph.D.
Dr. Zachary Roberts, M.D., Ph.D.
Executive Vice President - Research and Development, Chief Medical Officer
Executive Vice President - Research and Development, Chief Medical Officer
101.90K
-38.68%
Ms. Deborah M. (Debbie) Messemer
Ms. Deborah M. (Debbie) Messemer
Independent Director
Independent Director
45.96K
-44.53%
Mr. Todd B. Sisitsky
Mr. Todd B. Sisitsky
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
7.56M
-3.60%
Dr. David D Chang, M.D., Ph.D.
Dr. David D Chang, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
5.72M
-7.46%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
478.17K
-0.90%
Mr. Joshua A. Kazam
Mr. Joshua A. Kazam
Director
Director
303.06K
--
Mr. Owen N. Witte, M.D.
Mr. Owen N. Witte, M.D.
Independent Director
Independent Director
292.83K
+14.59%
Mr. Benjamin Machinas (Ben) Beneski
Mr. Benjamin Machinas (Ben) Beneski
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
218.51K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 3 de ago
Actualizado: dom., 3 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Pfizer Inc
10.07%
TPG Capital, L.P.
8.56%
Citadel Advisors LLC
6.10%
Capital World Investors
5.61%
Lynx1 Capital Advisors LLC
5.06%
Other
64.61%
Accionistas
Accionistas
Proporción
Pfizer Inc
10.07%
TPG Capital, L.P.
8.56%
Citadel Advisors LLC
6.10%
Capital World Investors
5.61%
Lynx1 Capital Advisors LLC
5.06%
Other
64.61%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
34.01%
Hedge Fund
16.69%
Private Equity
14.32%
Corporation
10.60%
Investment Advisor/Hedge Fund
10.50%
Individual Investor
7.08%
Research Firm
5.09%
Venture Capital
0.83%
Bank and Trust
0.16%
Other
0.72%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
408
225.54M
103.12%
-7.62M
2025Q1
437
219.29M
100.27%
-22.18M
2024Q4
434
209.87M
100.10%
-25.68M
2024Q3
441
205.03M
101.51%
-25.11M
2024Q2
447
205.90M
102.27%
+9.93M
2024Q1
446
170.59M
100.21%
-14.52M
2023Q4
455
160.71M
95.67%
-29.40M
2023Q3
461
177.28M
107.46%
-30.31M
2023Q2
461
179.96M
123.50%
-2.72M
2023Q1
465
163.54M
112.33%
-14.45M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Pfizer Inc
22.03M
10.07%
--
--
Mar 31, 2025
TPG Capital, L.P.
18.72M
8.56%
--
--
Mar 31, 2025
Citadel Advisors LLC
10.20M
4.66%
+4.85M
+90.75%
Mar 31, 2025
Capital World Investors
12.27M
5.61%
+5.37M
+77.85%
Mar 31, 2025
Lynx1 Capital Advisors LLC
11.06M
5.06%
+182.29K
+1.68%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
10.81M
4.94%
-33.81K
-0.31%
Mar 31, 2025
Darwin Global Management Ltd
10.45M
4.78%
+10.45M
--
Mar 31, 2025
The Vanguard Group, Inc.
8.07M
3.69%
+91.07K
+1.14%
Mar 31, 2025
Belldegrun (Arie S)
7.56M
3.46%
-282.53K
-3.60%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.39M
3.38%
-16.37M
-68.89%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
WisdomTree BioRevolution Fund
0.78%
Virtus LifeSci Biotech Clinical Trials ETF
0.73%
Invesco NASDAQ Future Gen 200 ETF
0.44%
Global X Genomics & Biotechnology ETF
0.2%
Zacks Small/Mid Cap ETF
0.14%
iShares Health Innovation Active ETF
0.04%
JPMorgan Fundamental Data Science Small Core ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Biotechnology ETF
0.02%
Ver más
WisdomTree BioRevolution Fund
Proporción0.78%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.73%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.44%
Global X Genomics & Biotechnology ETF
Proporción0.2%
Zacks Small/Mid Cap ETF
Proporción0.14%
iShares Health Innovation Active ETF
Proporción0.04%
JPMorgan Fundamental Data Science Small Core ETF
Proporción0.04%
Invesco Nasdaq Biotechnology ETF
Proporción0.03%
ProShares Ultra Nasdaq Biotechnology
Proporción0.03%
iShares Biotechnology ETF
Proporción0.02%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
